13F HOLDINGS REPORT
Aisling Capital Management LP
Quarter ended Q3 2024 · Filed November 13, 2024 · Accession 0002042586-24-000002
Total Value
$261.1M
Positions
16
Other Managers
0
Confidential Omitted
No
Holdings (16)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | BridgeBio Pharma Inc. (BBIO) | BBIO | 6,068,125 | $154.5M | 59.18% |
| 2 | Verona Pharma plc (VRNA) | 925050106 | 1,115,352 | $32.1M | 12.29% |
| 3 | Syndax Pharmaceuticals, Inc. (SNDX) | SNDX | 1,025,000 | $19.7M | 7.56% |
| 4 | Bicara Therapeutics Inc. (BCAX) | BCAX | 568,919 | $14.5M | 5.55% |
| 5 | Biomea Fusion Inc (BMEA) | BMEA | 798,757 | $8.1M | 3.09% |
| 6 | Monte Rosa Therapeutics Inc (GLUE) | GLUE | 1,472,331 | $7.8M | 2.99% |
| 7 | Compass Pathways Plc (CMPS) | CMPS | 964,500 | $6.1M | 2.33% |
| 8 | Nuvation Bio Inc. (NUVB) | NUVB | 2,541,009 | $5.8M | 2.23% |
| 9 | Poseida Therapeutics Inc. (PSTX) | 73730P108 | 1,043,267 | $3.0M | 1.14% |
| 10 | Tectonic Therapeutic Inc (TECX) | TECX | 84,148 | $2.5M | 0.98% |
| 11 | CalciMedica, Inc. (CALC) | CALC | 521,114 | $2.3M | 0.88% |
| 12 | Elevation Oncology Inc (ELEV) | 28623U101 | 2,834,910 | $1.7M | 0.65% |
| 13 | Reneo Pharmaceuticals Inc (RPHM) | 75974E103 | 886,075 | $1.5M | 0.58% |
| 14 | Marker Therapeutics, Inc. (MRKR) | MRKR | 314,286 | $886,286 | 0.34% |
| 15 | Aclaris Therapeutics Inc (ACRS) | ACRS | 434,455 | $499,623 | 0.19% |
| 16 | Viracta Therapeutics Inc (VIRX) | 92765F108 | 288,571 | $66,371 | 0.03% |